Migdoel Cruz-Rodriguez, MD
Cardiovascular Disease · Anasco, PRNPI 1316333404
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 212 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Medtronic at 42.6% of the total.
Across 212 payments — averaging $38.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Boston Scientific$978
- Abbott$638
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$600
- AstraZeneca$451
- Amgen$426
- plus $2K from 15 others
What the payments were for
- Food & beverage$7,97498%
- Education$1692%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 53 | $3,466 |
| Boston Scientific | 25 | $978 |
| Abbott | 22 | $638 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $600 |
| AstraZeneca | 23 | $451 |
| Amgen | 6 | $426 |
| PBG Puerto Rico LLC | 22 | $386 |
| Boehringer Ingelheim | 3 | $275 |
| Johnson & Johnson | 7 | $212 |
| E.r. Squibb & Sons, L.L.C. | 8 | $133 |
| Pfizer Pharmaceuticals LLC | 2 | $102 |
| Merck | 3 | $101 |
| Novartis | 4 | $82 |
| Bayer | 1 | $66 |
| Chiesi USA, Inc. | 3 | $53 |
| Bayer Puerto Rico Inc. | 2 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $36 |
| Akcea Therapeutics, Inc. | 2 | $33 |
| Terumo Medical Corporation | 1 | $24 |
| Pfizer | 2 | $19 |
| CSL Behring | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$779
- COBALT DR MRI SURESCAN$267
- JARDIANCE$243
- Amplia MRI$233
- ONYX FRONTIER$135
- CryoConsole$133
- Repatha$125
- Crome$121
- Cobalt$119
- AURORA EV-ICD MRI SURESCAN$117
- VISA AF MRI VR SURESCAN$110
- Multi-Link Vision coronary stent system$106
- Watchman$106
- GENERAL - THERAPIES$105
How this compares
$8,143 in reported general payments places this provider in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $90,298 |
| FarxigaDapagliflozin Propanediol | 99 | $63,117 |
| XareltoRivaroxaban | 105 | $61,560 |
| JardianceEmpagliflozin | 11 | $6,803 |
| Metoprolol Succinate | 813 | $6,720 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 593 | $6,241 |
| Atorvastatin Calcium | 803 | $4,997 |
| Losartan Potassium | 700 | $4,904 |
| Rosuvastatin Calcium | 651 | $4,151 |
| Carvedilol | 584 | $3,231 |
| Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid | 37 | $3,165 |
| Amlodipine Besylate | 876 | $3,053 |
| Lisinopril | 795 | $2,657 |
| BystolicNebivolol Hcl | 12 | $2,253 |
| Irbesartan-HydrochlorothiazideIrbesartan/Hydrochlorothiazide | 102 | $2,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $90,298149 claims |
| AstraZenecaFarxiga | $451 | $63,11799 claims |
| Johnson & JohnsonXarelto | $212 | $61,560105 claims |
| Boehringer IngelheimJardiance | $275 | $6,80311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in Anasco
- Karen Rodriguez MaldonadoMayaguez$231K
- Jose NovoaBayamon$209K
- Manuel GuzmanSan Juan$203K
- Luis Rosado CarrilloGuaynabo$173K
- Jorge GonzalezCaguas$114K
- Luis GelyCaguas$89K
- Luis Renta RosaCarolina$83K
- Ramon PereaSan Juan$68K
- Denis Ruiz SerranoGuaynabo$66K
- Francisco Merced-OrtizSan Juan$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.